Trial flop prompts major overhaul at Merrimack

9 November 2018

Shares in West Coast, USA-based Merrimack Pharmaceuticals (Nasdaq: MACK) have dipped around 5% after the firm mixed bad clinical news and an extensive corporate restructuring program into its quarterly results statement.

The firm previously announced negative results from an interim analysis of its Phase II SHERLOC study of MM-121 (seribantumab) in non-small cell lung cancer, stripping a fifth from the value of its stock.

Merrimack now says it is discontinuing development of all ongoing MM-121 programs, including the SHERBOC study, a companion Phase II clinical trial evaluating MM-121 in metastatic breast cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK